Ethyl-(2-methoxy-ethyl)-propyl-amine | 139709-39-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Ethyl-(2-methoxy-ethyl)-propyl-amine
• 英文别名: N-ethyl-N-(2-methoxyethyl)propan-1-amine
• CAS: 139709-39-0
• 化学式: C₈H₁₉NO
• 分子量: 145.24
• InChiKey: LITBYOMEOMSVGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• INHIBITORS OF HIV REPLICATION
  申请人：STURINO Claudio

  公开号：US20100261714A1

  公开（公告）日：2010-10-14

  Compounds of formula (I): wherein R 1 , R 2 , A 1 , A 2 , A 3 , A 4 , X and Y are as defined herein, are useful as inhibitors of HIV replication.

  式(I)的化合物： 其中R1、R2、A1、A2、A3、A4、X和Y如本文所定义，可用作HIV复制抑制剂。
• CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS
  申请人：MAILLIET Patrick

  公开号：US20090226411A1

  公开（公告）日：2009-09-10

  The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

  本发明涉及癌症治疗以及具有相当特异作用机制的新型抗癌剂。它还涉及新型化学化合物以及它们在人类治疗中的治疗应用。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• Oligomer-Containing Benzamide-Based Compounds
  申请人：NEKTAR THERAPEUTICS

  公开号：US20150250894A1

  公开（公告）日：2015-09-10

  The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

  本发明涉及含寡聚物的苯甲酰胺基化合物等。本发明的化合物相比缺乏寡聚物的相应化合物表现出一种或多种优点。
• 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2109605B1

  公开（公告）日：2013-02-20